FY2020 EPS Estimates for Collegium Pharmaceutical Inc Lifted by Jefferies Group (COLL)

Collegium Pharmaceutical Inc (NASDAQ:COLL) – Jefferies Group boosted their FY2020 earnings per share (EPS) estimates for Collegium Pharmaceutical in a research note issued on Sunday. Jefferies Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will post earnings of $1.11 per share for the year, up from their prior estimate of $0.93. Jefferies Group currently has a “Buy” rating and a $32.00 target price on the stock.

A number of other research firms have also weighed in on COLL. Janney Montgomery Scott set a $26.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Piper Jaffray Companies set a $33.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, January 23rd. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Monday, November 13th. Needham & Company LLC upped their price target on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. Finally, HC Wainwright reiterated a “buy” rating and issued a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $27.17.

Collegium Pharmaceutical (NASDAQ:COLL) traded up $1.85 on Tuesday, hitting $23.62. 1,908,600 shares of the company’s stock were exchanged, compared to its average volume of 667,555. The company has a market capitalization of $768.14 and a price-to-earnings ratio of -7.94. Collegium Pharmaceutical has a fifty-two week low of $7.37 and a fifty-two week high of $26.77.

Several hedge funds have recently added to or reduced their stakes in COLL. Bank of New York Mellon Corp lifted its holdings in shares of Collegium Pharmaceutical by 60.7% in the second quarter. Bank of New York Mellon Corp now owns 104,961 shares of the specialty pharmaceutical company’s stock worth $1,313,000 after buying an additional 39,656 shares in the last quarter. Alliancebernstein L.P. raised its stake in Collegium Pharmaceutical by 76.9% during the second quarter. Alliancebernstein L.P. now owns 27,600 shares of the specialty pharmaceutical company’s stock valued at $345,000 after purchasing an additional 12,000 shares in the last quarter. Teachers Advisors LLC raised its stake in Collegium Pharmaceutical by 98.8% during the second quarter. Teachers Advisors LLC now owns 59,590 shares of the specialty pharmaceutical company’s stock valued at $745,000 after purchasing an additional 29,617 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in Collegium Pharmaceutical by 44.0% during the second quarter. TIAA CREF Investment Management LLC now owns 61,187 shares of the specialty pharmaceutical company’s stock valued at $765,000 after purchasing an additional 18,691 shares in the last quarter. Finally, Nationwide Fund Advisors raised its stake in Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock valued at $161,000 after purchasing an additional 2,802 shares in the last quarter. 82.40% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Chairman Michael Thomas Heffernan sold 20,000 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total value of $500,200.00. Following the transaction, the chairman now owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alison B. Fleming sold 4,601 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the transaction, the insider now directly owns 28,513 shares in the company, valued at approximately $491,849.25. The disclosure for this sale can be found here. Insiders sold 1,105,558 shares of company stock worth $19,346,677 in the last three months. Insiders own 25.76% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “FY2020 EPS Estimates for Collegium Pharmaceutical Inc Lifted by Jefferies Group (COLL)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/13/fy2020-eps-estimates-for-collegium-pharmaceutical-inc-lifted-by-jefferies-group-coll.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply